Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection | Zendy

Álvaro H. Borges | Zendy; Jacqueline Neuhaus | Zendy; Abdel G. Babiker | Zendy; Keith Henry | Zendy; Mamta K. Jain | Zendy; Adrian Palfreeman | Zendy; Peter Mugyenyi | Zendy; Peré Domingo | Zendy; Christian Hoffmann | Zendy; Tim Read | Zendy; Sanjay Pujari | Zendy; Michael Meulbroek | Zendy; Margaret A. Johnson | Zendy; Timothy Wilkin | Zendy; Ronald T. Mitsuyasu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection

Author(s) -

Álvaro H. Borges,

Jacqueline Neuhaus,

Abdel G. Babiker,

Keith Henry,

Mamta K. Jain,

Adrian Palfreeman,

Peter Mugyenyi,

Peré Domingo,

Christian Hoffmann,

Tim Read,

Sanjay Pujari,

Michael Meulbroek,

Margaret A. Johnson,

Timothy Wilkin,

Ronald T. Mitsuyasu

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw621

Subject(s) - antiretroviral therapy , human immunodeficiency virus (hiv) , medicine , infection risk , cancer therapy , oncology , cancer , virology , immunology , intensive care medicine , viral load

In the Strategic Timing of Antiretroviral Treatment (START) study, immediate combination antiretroviral therapy (cART) initiation reduced cancer risk by 64%. We hypothesized that risk reduction was higher for infection-related cancer and determined by differences in CD4 cell counts and human immunodeficiency virus (HIV) RNA between the study arms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research